GLP-1 Receptor Agonist Market Size & Share Report, 2032

GLP-1 Receptor Agonist Market - By Drug Class, By Route of Administration, By Application, By Distribution, Global Forecast, 2024 – 2032

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology &amp; Scope

1.1&nbsp;&nbsp;&nbsp; Market scope &amp; definitions

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Base estimates &amp; calculations

1.3.1&nbsp;&nbsp;&nbsp; Base year calculation

1.3.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.4&nbsp;&nbsp;&nbsp; Forecast model

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.5.2&nbsp;&nbsp;&nbsp; Data mining sources

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary

2.1&nbsp;&nbsp;&nbsp; Industry 3600 synopsis

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Increasing prevalence of chronic diseases such as diabetes and obesity

3.2.1.2&nbsp;&nbsp;&nbsp; Increasing R&amp;D activities for developing novel therapeutics

3.2.1.3&nbsp;&nbsp;&nbsp; Formulation advancements of oral GLP-1 receptor agonists

3.2.1.4&nbsp;&nbsp;&nbsp; Increasing awareness about diagnosis and treatment options for diabetes

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls &amp; challenges

3.2.2.1&nbsp;&nbsp;&nbsp; Adverse effects associated with few GLP-1 agonist drugs

3.2.2.2&nbsp;&nbsp;&nbsp; Product recalls by market players

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.3.1&nbsp;&nbsp;&nbsp; By drug class

3.3.2&nbsp;&nbsp;&nbsp; By route of administration

3.3.3&nbsp;&nbsp;&nbsp; By application

3.3.4&nbsp;&nbsp;&nbsp; By distribution channel

3.4&nbsp;&nbsp;&nbsp; Clinical trial analysis

3.5&nbsp;&nbsp;&nbsp; Regulatory landscape

3.6&nbsp;&nbsp;&nbsp; Porter&rsquo;s analysis

3.7&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2022

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company matrix analysis

4.3&nbsp;&nbsp;&nbsp; Global company market share analysis

4.4&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.5&nbsp;&nbsp;&nbsp; Strategic dashboard

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Drug Class (USD Million)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; Semaglutide

5.3&nbsp;&nbsp;&nbsp; Dulaglutide

5.4&nbsp;&nbsp;&nbsp; Liraglutide

5.5&nbsp;&nbsp;&nbsp; Exenatide

5.6&nbsp;&nbsp;&nbsp; Other drug classes

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration (USD Million)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Parenteral

6.3&nbsp;&nbsp;&nbsp; Oral

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application (USD Million)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Type 2 diabetes mellitus

7.3&nbsp;&nbsp;&nbsp; Obesity

7.4&nbsp;&nbsp;&nbsp; Other applications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Distribution Channel (USD Million)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospital pharmacies

8.3&nbsp;&nbsp;&nbsp; Retail pharmacies

8.4&nbsp;&nbsp;&nbsp; Online pharmacies

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region (USD Million)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Switzerland

9.3.7&nbsp;&nbsp;&nbsp; Rest of Europe

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; China

9.4.2&nbsp;&nbsp;&nbsp; Japan

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.4.6&nbsp;&nbsp;&nbsp; Rest of Asia Pacific

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Rest of Latin America

9.6&nbsp;&nbsp;&nbsp; Middle East &amp; Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; Rest of Middle East &amp; Africa

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles

10.1&nbsp;&nbsp;&nbsp; Eli Lilly and Company

10.2&nbsp;&nbsp;&nbsp; Sanofi

10.3&nbsp;&nbsp;&nbsp; Novo-Nordisk A/S

10.4&nbsp;&nbsp;&nbsp; AstraZeneca

10.5&nbsp;&nbsp;&nbsp; Pfizer, Inc.

10.6&nbsp;&nbsp;&nbsp; Amgen, Inc.

10.7&nbsp;&nbsp;&nbsp; Innovent Biologics, Inc.

10.8&nbsp;&nbsp;&nbsp; PegBio Co., Ltd.

10.9&nbsp;&nbsp;&nbsp; Sun Pharmaceutical Industries Ltd.

10.10&nbsp;&nbsp;&nbsp; Boehringer Ingelheim International GmbH

&nbsp;&nbsp;&nbsp;

GLP-1 Receptor Agonist Market

Inquiry Before Buying

Industries

Information

Link

Global Headquarters